Amoéba Postpones Biocontrol Applications in the U.S., Commercialization Slightly Delayed

 In E3, EMEA, FVEY, France, P5

In France, Amoéba announces its 2020 half-year results which were in line with those of 2019 and continues to develop its biocide and biocontrol applications, albeit with some areas slight­ly delayed such as the appli­ca­tion for the mar­ket­ing of the bio­cide activ­i­ty in the United States, pre­vi­ous­ly planned for mid-2020 is post­poned and will be sub­mit­ted at the end of 2020.

The com­mer­cial­iza­tion of bio­con­trol prod­ucts con­tain­ing the active sub­stance (amoeba Willaertia magna C2c Maky amoeba lysate) is envis­aged by Amoeba in 2024 in Europe and in the first half of 2022 in the United States (sub­mis­sion envis­aged in July 2020, post­poned to September 2020).

As the Company’s Regulatory Affairs depart­ment worked on the mar­ket­ing autho­riza­tion of the bio­con­trol appli­ca­tion as a pri­or­i­ty, the appli­ca­tion for the mar­ket­ing of the bio­cide activ­i­ty in the United States, pre­vi­ous­ly planned for mid-2020 has been post­poned and will be sub­mit­ted at the end of 2020 with a first mar­ket­ing in the United States esti­mat­ed for the first half of 2022.

Amoéba is receiv­ing numer­ous requests to inte­grate its solu­tion into exist­ing appli­ca­tions (bio­cide and bio­con­trol) in new fields.

Print Friendly, PDF & Email

Tags: , ,

Category: Fuels

Biofuels Digest source|articles

Recommended Posts
0

Start typing and press Enter to search